Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.

Study Overview

• Status: Terminated
• Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
• Intervention / Treatment: Drug: Zevalin; Drug: Y-90-Zevalin; Drug: Rituximab; Drug: In-111 Zevalin

• Study Type: Interventional
• Enrollment (Actual): 79
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Adelaide, Australia
    • Royal Adelaide Hospital
  • Geelong, Australia, 3220
    • Barwon Health
  • Melbourne, Australia
    • Western Hospital
  • Tasmania
    • Hobart, Tasmania, Australia, 7001
      • Royal Hobart Hospital
  • Victoria
    • Parkville, Victoria, Australia, 3052
      • Royal Melbourne
• Austria
  • Vienna, Austria, A-1090
    • Medizinische Universität Wien -AKH Wien
• Belgium
  • Bruxelles, Belgium, 1000
    • Nuclear Medicine Physician, Jules Bordet Institute
  • Leuven, Belgium, 3000
    • University Hospital Gasthuisberg
• Canada
  • Ontario
    • Thunder Bay, Ontario, Canada, P7B 6V4
      • Thunder Bay Regional Health Sciences Centre-Regional Cancer Care
    • Toronto, Ontario, Canada
      • Sunnybrook Research Institute
  • Quebec
    • Greenfield Park, Quebec, Canada, J4V2H1
      • CSSS Champlain Charles LeMoyne
• France
  • Amiens, France, 80054
    • CHU Amiens, Hôpital Sud
  • Avignon, France, 84902
    • Ch Avignon
  • Bayonne, France, 64109
    • CH de la Côte Basque, Service d'Hématologie
  • Besancon, France, 25030
    • Hématologie - CHU Jean Minjoz
  • Bordeaux, France, 33076
    • Institut Bergonie
  • Brest, France, 29609
    • Hôpital Morvan - CHU Brest
  • Caen, France, 14076
    • Centre François Baclesse, Comite Hématologie
  • Creteil, France, 94010
    • Hopital Henri Mondor
  • La Roche-sur-Yon, France, 85925
    • CHD Vendee
  • Lille, France, 59037
    • CHRU Lille- Hospital Claude Huriez
  • Marseille, France, 13273
    • Institut Paoli-Calmettes
  • Metz, France, 57085
    • CHR Metz-Thionville
  • Mulhouse, France, 68100
    • CH de Mulhouse - Hôpital Emile Muller
  • Nice, France, 06189
    • Centre Antoine Lacassagne
  • Orleans, France, 45100
    • CHR Orléans
  • Paris, France, 75005
    • Institut Curie
  • Perpignan, France, 66000
    • Centre Hospitalier Saint Jean
  • Pessac, France, 33600
    • Hôpital Haut-Levêque Centre F.Magendie
  • Pontoise, France, 95303
    • Centre Hospitalier René Dubos,
  • Rouen, France, 76038
    • Service d'Hématologie Centre Henri Becquerel
  • Vandoeuvre-les-nancy, France, 54511
    • CHU de Brabios
  • Cedex
    • Limoges, Cedex, France, 87042
      • Chu Dupuytren
  • Cedex 9
    • Grenoble, Cedex 9, France, 38043
      • CHU A Michallon
• Ireland
  • Dublin, Ireland, 8
    • St James 's Hospital
  • Galway, Ireland
    • University Hospital Galway
• Israel
  • Beersheba, Israel, 84101
    • Soroka Medical Centre
  • Haifa, Israel
    • Rambam Health Care Campus
  • Jerusalem, Israel, 91120
    • Hadassah Medical Organization
  • Jerusalem, Israel, 93722
    • Shaare Zedek Medical Center
  • Tel Aviv, Israel, 64239
    • Tel Aviv Sourasky Medical Centre
  • Tel-Hashomer, Israel, 52621
    • Chaim Sheba Medical Center
• Italy
  • Bologna, Italy, 40138
    • Policlinico S Orsola Malpighi, Istituto di Ematologia ''L.e A. Seragnoli''
  • Brescia, Italy, 25123
    • New Ematologia dell'Ospedale "Spedali Civili" di Brescia
  • Milano, Italy, 20141
    • Divisione di Ematoncologia
  • Roma, Italy, 00189
    • Azienda Ospedaliera Sant'Andrea
  • Torino, Italy, 10126
    • Azienda Ospedaliera San. Giovanni Battista di Torino, Dipartimento di Oncologia U.O.A Ematologia, Le Molinette,
• Netherlands
  • Amersfoort, Netherlands, 3813 TZ
    • Meander Medisch Centrum
  • Amsterdam, Netherlands, 1081
    • VU Medisch Centrum
  • Den Haag, Netherlands, 2545 CH
    • Haga ziekenhuis
  • Groningen, Netherlands, 9713GZ
    • University Medical Centre Groningen (UMCG)
  • Hoofddorp, Netherlands, 2134TM
    • Spaarne Ziekenhuis, Internal Medicine/Ocology
  • Leeuwarden, Netherlands, 8934 AD
    • Medisch Centrum Leeuwarden
  • Nieuwegein, Netherlands, 3435 CM
    • St. Antonius Hospital
  • Nijmegen, Netherlands, 6525
    • University Medical Center Radboud Nijmegen
  • Rotterdam, Netherlands, NL-3015
    • Erasmus Medisch Centrum
• Puerto Rico
  • San Juan, Puerto Rico, 00918
    • Auxilio Mutuo Cancer Center
• Spain
  • Pamplona, Spain
    • Clinica Universidad de Navarra (CUN)
  • Zaragoza, Spain, 50009
    • Hospital Universitario Miguel Servet
  • Zaragoza, Spain
    • Miguel Servet University Hospital
• United Kingdom
  • Bristol, United Kingdom, BS2 8HW
    • Department of Haematology Bristol Royal Infirmary
  • Dorset, United Kingdom, BH15
    • Poole General Hospital
  • Glasgow, United Kingdom, G12 0YN
    • Beatson Cancer Centre
  • London, United Kingdom, SE5 9RS
    • King's College Hospital
  • Manchester, United Kingdom, M20 4BX
    • The Christie NHS Foundation Trust, The Christie Hospital,
• United States
  • Arizona
    • Casa Grande, Arizona, United States, 85122
      • Cancer Treatment Services Arizona
  • California
    • Berkeley, California, United States, 94704
      • Sutter East Bay Hospitals
    • Duarte, California, United States, 91010
      • City of Hope
  • Florida
    • Daytona Beach, Florida, United States, 32114
      • Halifax Health Medical Center
    • Tampa, Florida, United States, 33612
      • H. Lee Moffitt Cancer Center
  • Georgia
    • Atlanta, Georgia, United States, 30318
      • Piedmont Hospital Cancer Center
  • Idaho
    • Boise, Idaho, United States, 83712
      • St. Luke's Mountain States Tumor Institute (MSTI)
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
    • Chicago, Illinois, United States, 60611
      • Northwestern University Feinberg School of Medicine
    • Decatur, Illinois, United States, 62526
      • Decatur Memorial Hospital Cancer Care Specialists of Central Illinois
    • Niles, Illinois, United States, 60714
      • Illinois Cancer Specialists
    • Zion, Illinois, United States, 60099
      • Midwestern Regional Medical Center
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa Hospitals and Clinics
  • Kentucky
    • Louisville, Kentucky, United States, 40207
      • Norton Cancer Institute, Suburban
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Beth Israel Deaconess Medical Center
  • Michigan
    • Grosse Pointe Woods, Michigan, United States, 48236
      • St. John Hospital and Medical Center
  • Minnesota
    • Saint Louis Park, Minnesota, United States, 55426
      • Oncology Research-Park Nicollet Institute
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Saint Louis University
  • Nevada
    • Henderson, Nevada, United States, 89044
      • Comprehensive Cancer Centers of Nevada
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Hackensack UMC / John Theurer Cancer Center
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan-Kettering Cancer Center
  • Pennsylvania
    • Gettysburg, Pennsylvania, United States, 17325
      • Adams Cancer Center
    • York, Pennsylvania, United States, 17403
      • York Cancer Center / Cancer Care Associates of York
  • South Carolina
    • Greenville, South Carolina, United States, 29601
      • Saint Francis Hospital
  • South Dakota
    • Sioux Falls, South Dakota, United States, 57105
      • Avera Hematology and Transplant
  • Tennessee
    • Chattanooga, Tennessee, United States, 37421
      • Associates in Oncology and Hematology
  • Texas
    • Houston, Texas, United States, 77030
      • The University of Texas M.D. Anderson Cancer Center
  • Washington
    • Seattle, Washington, United States, 98109
      • Seattle Cancer Care Alliance

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Participant was 60-years of age or older at time of randomization
2. Histologically confirmed Ann Arbor stage II, III, or IV diffuse large B-cell lymphoma (DLBCL); or follicular lymphoma (FCL) Grade 3B according to the Revised European American lymphoma (REAL)/ World health organization (WHO) classification (from initial diagnosis made prior to starting R-CHOP therapy. Results from a pre R-CHOP marrow shall be available for review.
3. Local pathology review confirming the DLBCL diagnosis and cluster of differentiation 20 (CD20) positivity, and no evidence of DLBCL in bone marrow upon confirmation of complete remission (CR).
4. A paraffin block or original slides available for confirmatory pathology review. Participants may be randomized based on the local pathology result.
5. Age-adjusted international prognostic index (IPI) of 1, 2, or 3. The age-adjusted IPI was defined by one point for Lactate dehydrogenase (LDH) > upper limit of normal (ULN); Stage III or IV; and Karnofsky performance status <80% or WHO/ eastern cooperative operations group (ECOG) performance status >1.
6. First-line treatment of DLBCL must have been 6 cycles of standard R-CHOP21, R-CHOP14 or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) chemotherapy. Participants who received pre-phase therapy for the purpose of improving performance status prior to initiating R-CHOP are eligible.
7. Complete remission (CR) according to the International Workshop Response Criteria for non-Hodgkin's lymphoma (NHL) described by Cheson et al after first-line treatment. Computerized tomography (CT) scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of chemotherapy. Applicability of the neck CT means that the participant had involvement of the neck region by palpation / physical examination at first diagnosis.
8. A negative Fluorine-18-deoxyglucose positron emission tomography (FDG-PET) scan confirming complete response, with negative defined as a score of 1-3 on the Deauville 5-point scale used to quantify radionucleotide density in PET scans as determined locally (Morschhauser 200735).
9. Bone marrow cellularity greater than 15%, no evidence of myelodysplasia morphologically and no evidence of involvement with lymphoma either at the pre R-CHOP marrow or on repeat assessment pre-Zevalin. After completing R-chemotherapy, a repeat marrow is required for participant randomized to the Zevalin arm only.
10. A world health organization/eastern cooperative oncology group (WHO/ECOG) performance status of 0, 1 or 2.
11. Adequate hematopoietic functions: Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/ liter (L), Hemoglobin (Hgb) ≥ 9 g/dL, Platelets ≥ 100 x 10^9/L.
12. Life expectancy of 6 months or longer.
13. Written informed consent obtained according to local guidelines.

Exclusion Criteria:

1. Presence of any other malignancy or history of prior malignancy within 5 years of study entry. Within 5 years, participants treated for Stage I or II cancers are eligible provided they have a life expectancy of > 5 years. The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ cervical cancer.
2. Prior radioimmunotherapy, including radiation therapy for Non-Hodgkin's lymphoma) NHL, or any other NHL therapy.
3. Presence of primary gastric, central nervous system (CNS), or testicular lymphoma at first diagnosis.
4. Histological transformation of low-grade NHL.
5. Active hepatitis B or C.
6. Known history of human immunodeficiency virus (HIV) infection.
7. Abnormal liver function: total bilirubin > 2 × ULN unless secondary to Gilbert disease.
8. Abnormal renal function: serum creatinine > 2.0 × ULN.
9. Non-recovery from the toxic effects of chemotherapy to < grade 2, or interfering with Zevalin treatment.
10. Known hypersensitivity to murine or chimeric antibodies or proteins.
11. Granulocyte-colony stimulating factor (G-CSF) or Granulocyte macrophage-colony stimulating factor (GM-CSF) therapy within 4 weeks prior to Zevalin or observation.
12. Concurrent severe and/or medically uncontrolled disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study.
13. Treatment with investigational drugs less than 4 weeks prior to Zevalin or observation.
14. Major surgery less than 4 weeks prior to Zevalin or start of observation.
15. Concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment. Participants on a chronic dose of prednisone for a medical condition (e.g. Asthma or autoimmune disease) less than or equal to 20 milligram (mg) daily, stable for 4 weeks, are permissible.
16. Unwillingness or inability to comply with the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Zevalin; Participants received rituximab 250 milligram per meter square (mg/m^2) by intravenous infusion on Day 1. If required by the governing regulatory agency, rituximab was to be followed 4 hours later by In-111-Zevalin 5.0 millicurie (mCi) on Day 1. And on Days 7-9: participants received rituximab 250 mg/m^2 by intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie/kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in participants with a platelet count in 100,000/ microliter [μL] to 149,000/μL).	Drug: Zevalin; Zevalin administered intravenous infusion.; Other Names: Ibritumomab Tiuxetan; Drug: Y-90-Zevalin; Y-90-Zevalin administered by intravenous infusion.; Drug: Rituximab; Rituximab administered by intravenous infusion.; Drug: In-111 Zevalin; In-111-Zevalin administered by intravenously.
No Intervention: Observation; Participants who were randomized in this arm group did not receive any anti-lymphoma therapy unless they had a relapse of their disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS) for Living Participants	OS was the time from randomization to death. In living participants, survival time was censored on the last date that participants were known to be alive. OS for living participant was calculated as (end of study date/last visit date - randomization date)+ 1/30.4375. Overall Survival was summarized separately for living participants as only few participants died in this study.	From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years)
Overall Survival for Death	OS was the time from randomization to death. OS for death calculated as (date of death - randomization date)+ 1/30.4375. Overall Survival was summarized separately for participants who were died as only few participants died in this study.	From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	PFS was defined as the time interval between the date of randomization and the date of relapse or death from any cause.	From randomization till death or end of study, whichever occurs first (Up to approximately 2.5 years)
Overall Survival Rate at 24 Months	The OS rate at 24-month defined as the percentage of all randomized participants who died within 24 months of randomization.	24 Months

Collaborators and Investigators

• Sponsor: Spectrum Pharmaceuticals, Inc

Study record dates

Study Major Dates

• Study Start (Actual): April 19, 2012
• Primary Completion (Actual): October 23, 2014
• Study Completion (Actual): October 23, 2014

Study Registration Dates

• First Submitted: January 6, 2012
• First Submitted That Met QC Criteria: January 12, 2012
• First Posted (Estimate): January 13, 2012

Study Record Updates

• Last Update Posted (Actual): December 16, 2021
• Last Update Submitted That Met QC Criteria: November 18, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Rituximab; Antibodies, Monoclonal
• Other Study ID Numbers: SPI-ZEV-11-301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No